| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trials |
1 Beth Israel Deaconess Medical Center and 2 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
Purpose: Dendritic cells (DCs) are potent antigen-presenting cells that are uniquely capable of inducing tumor-specific immune responses. We have conducted a Phase I trial in which patients with metastatic breast and renal cancer were treated with a vaccine prepared by fusing autologous tumor and DCs.
Experimental Design: Accessible tumor tissue was disrupted into single cell suspensions. Autologous DCs were prepared from adherent peripheral blood mononuclear cells that were obtained by leukapheresis and cultured in granulocyte macrophage colony-stimulating factor, interleukin 4, and autologous plasma. Tumor cells and DCs were cocultured in the presence of polyethylene glycol to generate the fusions. Fusion cells were quantified by determining the percentage of cells that coexpress tumor and DC markers. Patients were vaccinated with fusion cells at 3-week intervals and assessed weekly for toxicity, and tumor response was assessed at 1, 3, and 6 months after completion of vaccination.
Results: The vaccine was generated for 32 patients. Twenty-three patients were vaccinated with 1 x 105 to 4 x 106 fusion cells. Fusion cells coexpressed tumor and DC antigens and stimulated allogeneic T-cell proliferation. There was no significant treatment-related toxicity and no clinical evidence of autoimmunity. In a subset of patients, vaccination resulted in an increased percentage of CD4 and CD8+ T cells expressing intracellular IFN-
in response to in vitro exposure to tumor lysate. Two patients with breast cancer exhibited disease regressions, including a near complete response of a large chest wall mass. Five patients with renal carcinoma and one patient with breast cancer had disease stabilization.
Conclusions: Our findings demonstrate that fusion cell vaccination of patients with metastatic breast and renal cancer is a feasible, nontoxic approach associated with the induction of immunological and clinical antitumor responses.
This article has been cited by other articles:
|
|
 |
|
  L. C. Benavides, J. D. Gates, M. G. Carmichael, R. Patel, J. P. Holmes, M. T. Hueman, E. A. Mittendorf, D. Craig, A. Stojadinovic, S. Ponniah, et al. The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02 Clin. Cancer Res., April 15, 2009; 15(8): 2895 - 2904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Schuurhuis, P. Verdijk, G. Schreibelt, E. H.J.G. Aarntzen, N. Scharenborg, A. de Boer, M. W.M.M. van de Rakt, M. Kerkhoff, M.-J. P. Gerritsen, F. Eijckeler, et al. In situ Expression of Tumor Antigens by Messenger RNA-Electroporated Dendritic Cells in Lymph Nodes of Melanoma Patients Cancer Res., April 1, 2009; 69(7): 2927 - 2934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Vasir, Z. Wu, K. Crawford, J. Rosenblatt, C. Zarwan, A. Bissonnette, D. Kufe, and D. Avigan Fusions of Dendritic Cells with Breast Carcinoma Stimulate the Expansion of Regulatory T Cells while Concomitant Exposure to IL-12, CpG Oligodeoxynucleotides, and Anti-CD3/CD28 Promotes the Expansion of Activated Tumor Reactive Cells J. Immunol., July 1, 2008; 181(1): 808 - 821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A Teicher, J. M Yingling, and J. M McPherson TGF{beta} Blockade as Anticancer Therapy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 71 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Basu, S. Bhaumik, A. K. Haldar, K. Naskar, T. De, S. K. Dana, P. Walden, and S. Roy Hybrid Cell Vaccination Resolves Leishmania donovani Infection by Eliciting a Strong CD8+ Cytotoxic T-Lymphocyte Response with Concomitant Suppression of Interleukin-10 (IL-10) but Not IL-4 or IL-13 Infect. Immun., December 1, 2007; 75(12): 5956 - 5966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Teicher Transforming Growth Factor-{beta} and the Immune Response to Malignant Disease Clin. Cancer Res., November 1, 2007; 13(21): 6247 - 6251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Koido, E. Hara, S. Homma, M. Mitsunaga, A. Takahara, E. Nagasaki, H. Kawahara, M. Watanabe, Y. Toyama, S. Yanagisawa, et al. Synergistic Induction of Antigen-Specific CTL by Fusions of TLR-Stimulated Dendritic Cells and Heat-Stressed Tumor Cells J. Immunol., October 1, 2007; 179(7): 4874 - 4883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Park, M. E. Melisko, L. J. Esserman, L. A. Jones, J. B. Wollan, and R. Sims Treatment With Autologous Antigen-Presenting Cells Activated With the HER-2 Based Antigen Lapuleucel-T: Results of a Phase I Study in Immunologic and Clinical Activity in HER-2 Overexpressing Breast Cancer J. Clin. Oncol., August 20, 2007; 25(24): 3680 - 3687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ko, W. Luo, L. Peng, X. Wang, and S. Ferrone Mouse Dendritic-Endothelial Cell Hybrids and 4-1BB Costimulation Elicit Antitumor Effects Mediated by Broad Antiangiogenic Immunity Cancer Res., August 15, 2007; 67(16): 7875 - 7884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Savai, R. T. Schermuly, S. S. Pullamsetti, M. Schneider, S. Greschus, H. A. Ghofrani, H. Traupe, F. Grimminger, and G.-A. Banat A Combination Hybrid-Based Vaccination/Adoptive Cellular Therapy to Prevent Tumor Growth by Involvement of T Cells Cancer Res., June 1, 2007; 67(11): 5443 - 5453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Siddiqui, X. Frigola, S. Bonne-Annee, M. Mercader, S. M. Kuntz, A. E. Krambeck, S. Sengupta, H. Dong, J. C. Cheville, C. M. Lohse, et al. Tumor-Infiltrating Foxp3-CD4+CD25+ T Cells Predict Poor Survival in Renal Cell Carcinoma Clin. Cancer Res., April 1, 2007; 13(7): 2075 - 2081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Koido, E. Hara, S. Homma, A. Torii, M. Mitsunaga, S. Yanagisawa, Y. Toyama, H. Kawahara, M. Watanabe, S. Yoshida, et al. Streptococcal Preparation OK-432 Promotes Fusion Efficiency and Enhances Induction of Antigen-Specific CTL by Fusions of Dendritic Cells and Colorectal Cancer Cells J. Immunol., January 1, 2007; 178(1): 613 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Yang and R. Childs Immunotherapy for Renal Cell Cancer J. Clin. Oncol., December 10, 2006; 24(35): 5576 - 5583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schott Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers. Endocr. Relat. Cancer, September 1, 2006; 13(3): 779 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wierecky, M. R. Muller, S. Wirths, E. Halder-Oehler, D. Dorfel, S. M. Schmidt, M. Hantschel, W. Brugger, S. Schroder, M. S. Horger, et al. Immunologic and Clinical Responses after Vaccinations with Peptide-Pulsed Dendritic Cells in Metastatic Renal Cancer Patients Cancer Res., June 1, 2006; 66(11): 5910 - 5918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. T. Cohen and F. J. McGovern Renal-Cell Carcinoma N. Engl. J. Med., December 8, 2005; 353(23): 2477 - 2490. [Full Text] [PDF]
|
|
|
|
|
|
L A Emens, R T Reilly, and E M Jaffee Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity Endocr. Relat. Cancer, March 1, 2005; 12(1): 1 - 17. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
